A multi-centre prospective development study evaluating focal therapy using high intensity focused ultrasound for localised prostate cancer: The INDEX study

Contemporary Clinical Trials

Volumn 36, Issue 1, 2013, Pages 68-80

  Dickinson, L ^a,b   Ahmed, H U ^a,b   Kirkham, A P ^b   Allen, C ^b   Freeman, A ^b   Barber, J ^a   Hindley, R G ^c   Leslie, T ^d,e   Ogden, C ^f   Persad, R ^g   Winkler, M H ^h   Emberton, M ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^d OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e CHURCHILL HOSPITAL   (United Kingdom)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^h IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Focal therapy; High intensity focused ultrasound; IDEAL guidelines; Multi centre; Prospective study

Indexed keywords

ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER RISK; CANCER THERAPY; FOLLOW UP; GLEASON SCORE; HIGH INTENSITY FOCUSED ULTRASOUND; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREDICTIVE VALIDITY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE VOLUME; QUESTIONNAIRE; STUDY DESIGN; TREATMENT FAILURE; ULTRASOUND TRANSDUCER; UNITED KINGDOM;

FOCAL THERAPY; HIGH-INTENSITY FOCUSED ULTRASOUND; IDEAL GUIDELINES; MULTI-CENTRE; PROSPECTIVE STUDY;

HIGH-INTENSITY FOCUSED ULTRASOUND ABLATION; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RESEARCH DESIGN;

EID: 84880300908     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2013.06.005     Document Type: Article

References (55)

1. Barret E., Ahallal Y., Sanchez-Salas R., Galiano M., Cosset J.M., Validire P., et al. Morbidity of focal therapy in the treatment of localized prostate cancer. Eur Urol 2013, 63:618-622.
2. Ahmed H.U., Freeman A., Kirkham A., Sahu M., Scott R., Allen C., et al. Focal therapy for localized prostate cancer: a phase I/II trial. J Urol 2011, 185:1246-1254.
3. Ahmed H.U., Hindley R.G., Dickinson L., Freeman A., Kirkham A.P., Sahu M., et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 2012, 13:622-632.
4. Eggener S., Salomon G., Scardino P.T., De la Rosette J., Polascik T.J., Brewster S. Focal therapy for prostate cancer: possibilities and limitations. Eur Urol 2010, 58:57-64.
5. Hu J.C., Gu X., Lipsitz S.R., Barry M.J., D'Amico A.V., Weinberg A.C., et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 2009, 302:1557-1564.
6. Sanda M.G., Dunn R.L., Michalski J., Sandler H.M., Northouse L., Hembroff L., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358:1250-1261.
7. Resnick M.J., Koyama T., Fan K.H., Albertsen P.C., Goodman M., Hamilton A.S., et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013, 368:436-445.
8. Bill-Axelson A., Holmberg L., Ruutu M., Haggman M., Andersson S.O., Bratell S., et al. Watchful waiting and prostate cancer. NEJM 2005, 352:1977-1984.
9. Bill-Axelson A., Holmberg L., Ruutu M., Garmo H., Stark J.R., Busch C., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011, 364:1708-1717.
10. Wilt T.J., Brawer M.K., Jones K.M., Barry M.J., Aronson W.J., Fox S., et al. Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012, 367:203-213.
11. Bahn D., de Castro Abeu A.L., Gill I.S., Hung A.J., Silverman P., Gross M.E., et al. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7years. Eur Urol 2012, 62:55-63.
12. Walsh P.C. Response to letter to Editor from Lawrence Klotz re my Editorial Comment on focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. J Urol Nov 20 2012, [pii: S0022-5347(12)05592-9, [Epub ahead of print]]. 10.1016/j.juro.2012.11.088.
13. Ahmed H.U., Emberton M. Benchmarks for success in focal therapy of prostate cancer: cure or control?. World J Urol 2010, 28:577-582.
14. Smith D.W., Stoimenova D., Eid K., Barqawi A. The role of targeted focal therapy in the management of low-risk prostate cancer: update on current challenges. Prostate Cancer 2012, 2012:587139.
15. Langley S., Ahmed H.U., Al-Qaisieh B., Bostwick D., Dickinson L., Veiga F.G., et al. Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer. BJU Int 2012, 109(Suppl. 1):7-16.
16. Ahmed H.U., Akin O., Coleman J.A., Crane S., Emberton M., Goldenberg L., Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer (appendix) Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int 2012, 109:1636-1647.
17. De la Rosette J., Ahmed H., Barentsz J., Johansen T.B., Brausi M., Emberton M., et al. Focal therapy in prostate cancer - report from a consensus panel. J Endourol 2010, 24:775-780.
18. McCulloch P., Altman D.G., Campbell W.B., Flum D.R., Glasziou P., Marshall J.C., et al. No surgical innovation without evaluation: the IDEAL recommendations. Lancet 2009, 374:1105-1112.
19. http://www.mrc.ac.uk/Utilities/Documentrecord/index.htm?d=MRC004871.
20. Kirkham A.P., Emberton M., Allen C. How good is MRI at detecting and characterising cancer within the prostate?. Eur Urol 2006, 50:1163-1174.
21. Villers A., Puech P., Mouton D., Leroy X., Ballereau C., Lemaitre L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006, 176:2432-2437.
22. Bratan F., Niaf E., Melodelima C., Chesnais A.L., Souchon R., Mege-Lechevallier F., et al. Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol Mar 15 2013, [Epub ahead of print].
23. Dickinson L., Ahmed H.U., Allen C., Barentsz J.O., Carey B., Futterer J.J., et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 2011, 59:477-494.
24. Dickinson L., Ahmed H.U., Allen C., Barentsz J.O., Carey B., Futterer J.J., et al. Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway?. J Magn Reson Imaging 2013, 37:48-58.
25. Hu Y., Ahmed H.U., Carter T., bArumainayagam N., Lecornet E., Barzell W., et al. A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)-biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy. BJU Int 2012, 110:812-820.
26. Crawford E.D., Rove K.O., Barqawi A.B., Maroni P.D., Werahera P.N., Baer C.A., et al. Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate Nov 20 2012, [Epub ahead of print]. 10.1002/pros.22622.
27. Huber P., Debus J., Jenne J., Jochle K., van Kaick G., Lorenz W.J., et al. Therapeutic ultrasound in tumor therapy: principles, applications and new developments. Radiologe 1996, 36:64-71.
28. Ahmed H.U., Zacharakis E., Dudderidge T., Armitage J.N., Scott R., Calleary J., et al. High-intensity focused ultrasound in the treatment of primary prostate cancer: the first UK series. Br J Cancer 2009, 101:19-26.
29. Kirkham A.P., Emberton M., Hoh I.M., Illing R.O., Freeman A.A., Allen C. MR imaging of prostate after treatment with high-intensity focused ultrasound. Radiology 2008, 246:833-844.
30. Dickinson L., Hu Y., Ahmed H.U., Allen C., Kirkham A.P., Emberton M., et al. Image-directed, tissue-preserving focal therapy of prostate cancer: a feasibility study of a novel deformable MR-US registration system. BJU Int 2013, [in press]. 10.1111/bju.12223.
31. Hu Y., Ahmed H.U., Taylor Z., Allen C., Emberton M., Hawkes D.J., et al. MR to ultrasound registration for image-guided prostate interventions. Med Image Anal 2012, 16:687-703.
32. Hu Y., Carter T.J., Ahmed H.U., Emberton M., Allen C., Hawkes D.J., et al. Modelling prostate motion for data fusion during image-guided interventions. IEEE Trans Med Imaging 2011, 30:1887-1900.
33. Machin D., Campbell M., Tan S.B., Tan S.H. Sample size tables for clinical studies 2011, John Wiley & Sons. 3rd ed.
34. Ahmed H.U. The index lesion and the origin of prostate cancer. N Engl J Med 2009, 361:1704-1706.
35. Stamey T.A., Freiha F.S., McNeal J.E., Redwine E.A., Whittemore A.S., Schmid H.P. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993, 71(3 Suppl.):933-938.
36. Liu W., Laitinen S., Khan S., Vihinen M., Kowalski J., Yu G., et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009, 15:559-565.
37. Karavitakis M., Ahmed H.U., Abel P.D., Hazell S., Winkler M.H. Tumor focality in prostate cancer: implications for focal therapy. Nat Rev Clin Oncol 2011, 8:48-55.
38. Bott S.R., Ahmed H.U., Hindley R.G., Abdul-Rahman A., Freeman A., Emberton M. The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. BJU Int 2010, 106:1607-1611.
39. Karavitakis M., Winkler M., Abel P., Livni N., Beckley I., Ahmed H.U. Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis 2011, 14:46-52.
40. Ahmed H.U., Arya M., Freeman A., Emberton M. Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?. Lancet Oncol 2012, 13:e509-e517.
41. Nickel J.C., Speakman M. Should we really consider Gleason 6 prostate cancer?. BJU Int 2012, 109:645-646.
42. Carter H.B., Partin A.W., Walsh P.C., Trock B.J., Veltri R.W., Nelson W.G., et al. Gleason score 6 adenocarcinoma: should it be labeled as cancer?. J Clin Oncol 2012, 30:4294-4296.
43. Ahmed H.U., Hu Y., Carter T., Arumainayagam N., Lecornet E., Freeman A., et al. Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol 2011, 186:458-464.
44. http://clinicaltrials.gov/ct2/show/NCT00499174.
45. http://www.controlled-trials.com/ISRCTN59410552.
46. Mayer E., Piercy D., Kerr K., Lewis R., Karim O., Dasgupta P., et al. Randomised controlled trial (RCT) of laparoscopic, OPEn and robot-assisted prostatectomy as treatment for organ-confined prostate cancer. LopeRA feasibility study (CRUK/09/008). NCRI UK Annual Conference 2011, A49.
47. Crook J.M., Gomez-Iturriaga A., Wallace K., Ma C., Fung S., Alibhai S., et al. Comparison of health-related quality of life 5years after SPIRIT: surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol 2011, 29:362-368.
48. Wallace K., Fleshner N., Jewett M., Basiuk J., Crook J. Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol 2006, 24:4158-4162.
49. Donnelly B.J., Saliken J.C., Brasher P.M., Ernst S.D., Rewcastle J.C., Lau H., et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer 2010, 116:323-330.
50. Robinson J.W., Donnelly B.J., Siever J.E., Saliken J.C., Ernst S.D., Rewcastle J.C., et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes. Cancer 2009, 115:4695-4704.
51. Chin J.L., Ng C.K., Touma N.J., Pus N.J., Hardie R., Abdelhady M., et al. Randomized trial comparing cryoablation and external beam radiotherapy for T2C-T3B prostate cancer. Prostate Cancer Prostatic Dis 2008, 11:40-45.
52. Crawford E.D., Hussain M., DeAntoni E.P., Thompson I.M., Eisenberger M.A., Blumenstein B., et al. Southwest Oncology Group strategies in prostatic carcinoma. Semin Surg Oncol 1995, 11:60-64.
53. O'Reilly P., Martin L., Collins G. Few patients with prostate cancer are willing to be randomised to treatment. BMJ 1999, 318:1556.
54. Early closure of a randomized controlled trial of three treatment approaches to early localised prostate cancer: the MRC PR06 trial. BJU Int 2004, 94:1400-1401. PR06 Collaborators.
55. http://www.spcginfo.com/.